Suppr超能文献

用于早期阿尔茨海默病纵向研究的性别特异性综合量表。

Sex-specific composite scales for longitudinal studies of incipient Alzheimer's disease.

作者信息

Banks Sarah J, Shifflett Benjamin, Berg Jody-Lynn, Sundermann Erin, Peavy Guerry, Bondi Mark W, Edland Steven D

机构信息

Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.

Department of Family Medicine and Public Health, UCSD, La Jolla, CA.

出版信息

Alzheimers Dement (N Y). 2019 Oct 3;5:508-514. doi: 10.1016/j.trci.2019.07.003. eCollection 2019.

DOI:10.1016/j.trci.2019.07.003
PMID:31650007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6804506/
Abstract

INTRODUCTION

The impact of Alzheimer's disease (AD) on cognitive decline differs by sex. Composite scores are useful as singular outcomes in clinical trials, yet to date these have not been developed to measure sex-specific change.

METHOD

We derived optimal composites from component scales available in the AD Neuroimaging Initiative (ADNI) database among cognitively normal and mild cognitively impaired subjects who are cerebrospinal fluid amyloid-β positive for early AD. Maximally sensitive composites were constructed separately for men and women using standard formulas. We compared the statistical power of the composites with the ADNI Prodromal Alzheimer's Cognitive Composite.

RESULTS

Among 9 cognitive measures and clinical dementia rating sum of boxes, the optimal sex-specific composites included 5 measures, including the clinical dementia rating and 4 distinct cognitive measures. The sex-specific composites consistently outperformed sex-agnostic composites and the ADNI Prodromal Alzheimer's Cognitive Composite.

DISCUSSION

Sex-specific composite scales may improve the power of longitudinal studies of early AD and clinical trials.

摘要

引言

阿尔茨海默病（AD）对认知衰退的影响存在性别差异。综合评分在临床试验中作为单一结果很有用，但迄今为止尚未开发出用于衡量特定性别的变化的评分。

方法

我们从阿尔茨海默病神经影像倡议（ADNI）数据库中可获得的分量表中，为早期AD脑脊液淀粉样蛋白-β呈阳性的认知正常和轻度认知障碍受试者得出最佳综合评分。使用标准公式分别为男性和女性构建了最大敏感性综合评分。我们将这些综合评分的统计功效与ADNI前驱性阿尔茨海默病认知综合评分进行了比较。

结果

在9项认知测量和临床痴呆评定量表总和中，最佳性别特异性综合评分包括5项测量，包括临床痴呆评定量表和4项不同的认知测量。性别特异性综合评分始终优于无性别差异的综合评分和ADNI前驱性阿尔茨海默病认知综合评分。

讨论

性别特异性综合量表可能会提高早期AD纵向研究和临床试验的功效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97a9/6804506/757b7a71b9e6/gr1.jpg

相似文献

1
Sex-specific composite scales for longitudinal studies of incipient Alzheimer's disease.
Alzheimers Dement (N Y). 2019 Oct 3;5:508-514. doi: 10.1016/j.trci.2019.07.003. eCollection 2019.
2
Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study.
J Alzheimers Dis. 2015;46(4):1079-89. doi: 10.3233/JAD-143015.
3
Optimal Weighting of Preclinical Alzheimer's Cognitive Composite (PACC) Scales to Improve their Performance as Outcome Measures for Alzheimer's Disease Clinical Trials.
Int J Stat Med Res. 2023 Feb 15;12:90-96. doi: 10.6000/1929-6029.2023.12.12. Epub 2023 Sep 7.
4
Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
J Alzheimers Dis. 2015;47(1):231-42. doi: 10.3233/JAD-150128.
5
Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study.
Alzheimers Dement (N Y). 2019 Aug 7;5:364-373. doi: 10.1016/j.trci.2019.06.004. eCollection 2019.
6
Development and validation of language and visuospatial composite scores in ADNI.
Alzheimers Dement (N Y). 2020 Dec 5;6(1):e12072. doi: 10.1002/trc2.12072. eCollection 2020.
7
Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer's Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer's Disease Clinical Studies.
J Prev Alzheimers Dis. 2021;8(4):503-512. doi: 10.14283/jpad.2021.39.
8
Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE® AD02 in Early Alzheimer's Disease - Prospective Use of Novel Composite Scales.
J Prev Alzheimers Dis. 2015 Jun;2(2):91-102. doi: 10.14283/jpad.2015.67.
9
The structural MRI markers and cognitive decline in prodromal Alzheimer's disease: a 2-year longitudinal study.
Quant Imaging Med Surg. 2018 Nov;8(10):1004-1019. doi: 10.21037/qims.2018.10.08.
10
Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.
Alzheimers Dement. 2018 Aug;14(8):1077-1087. doi: 10.1016/j.jalz.2018.03.009. Epub 2018 May 9.

引用本文的文献

1
Maximizing utility of neuropsychological measures in sex-specific predictive models of incident Alzheimer's disease in the Framingham Heart Study.
Alzheimers Dement. 2024 Feb;20(2):1112-1122. doi: 10.1002/alz.13500. Epub 2023 Oct 26.
2
Molecular and subregion mechanisms of episodic memory phenotypes in temporal lobe epilepsy.
Brain Commun. 2022 Nov 5;4(6):fcac285. doi: 10.1093/braincomms/fcac285. eCollection 2022.
3
MicroRNAs as potential biomarkers in temporal lobe epilepsy and mesial temporal lobe epilepsy.
Neural Regen Res. 2023 Apr;18(4):716-726. doi: 10.4103/1673-5374.354510.
4
Anticholinergic Drug Burden and Neurocognitive Performance in the Study of Latinos-Investigation of Neurocognitive Aging.
J Alzheimers Dis. 2022;86(1):53-65. doi: 10.3233/JAD-215247.
5
Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels.
J Alzheimers Dis. 2021;84(1):119-128. doi: 10.3233/JAD-210640.
6
Verbal memory dysfunction is associated with alterations in brain transcriptome in dominant temporal lobe epilepsy.
Epilepsia. 2020 Oct;61(10):2203-2213. doi: 10.1111/epi.16673. Epub 2020 Sep 18.

本文引用的文献

1
FDA position statement "Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry".
Alzheimers Dement (N Y). 2019 Jan 10;5:13-19. doi: 10.1016/j.trci.2018.11.004. eCollection 2019.
2
Derivation of cutoffs for the Elecsys amyloid β (1-42) assay in Alzheimer's disease.
Alzheimers Dement (Amst). 2018 Aug 11;10:698-705. doi: 10.1016/j.dadm.2018.07.002. eCollection 2018.
3
Sex differences in Alzheimer's disease and common neuropathologies of aging.
Acta Neuropathol. 2018 Dec;136(6):887-900. doi: 10.1007/s00401-018-1920-1. Epub 2018 Oct 17.
4
Sex and age interact to determine clinicopathologic differences in Alzheimer's disease.
Acta Neuropathol. 2018 Dec;136(6):873-885. doi: 10.1007/s00401-018-1908-x. Epub 2018 Sep 15.
5
Sex differences in the association between apolipoprotein E ε4 allele and Alzheimer's disease markers.
Alzheimers Dement (Amst). 2018 Jul 7;10:438-447. doi: 10.1016/j.dadm.2018.06.004. eCollection 2018.
6
Measuring cognition and function in the preclinical stage of Alzheimer's disease.
Alzheimers Dement (N Y). 2018 Feb 13;4:64-75. doi: 10.1016/j.trci.2018.01.003. eCollection 2018.
7
Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts.
Alzheimers Dement. 2018 Sep;14(9):1193-1203. doi: 10.1016/j.jalz.2018.04.010. Epub 2018 May 24.
8
Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5.
Alzheimers Dement (N Y). 2017 Nov 10;3(4):668-677. doi: 10.1016/j.trci.2017.10.004. eCollection 2017 Nov.
9
Design of pilot studies to inform the construction of composite outcome measures.
Alzheimers Dement (N Y). 2017 Jun;3(2):213-218. doi: 10.1016/j.trci.2016.12.004. Epub 2017 Jan 23.
10
Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume.
Alzheimers Res Ther. 2017 Sep 12;9(1):72. doi: 10.1186/s13195-017-0300-8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验